Analysts See Opportunity in Jazz (JAZZ) Sell-Off
Tweet Send to a Friend
Cantor Fitzgerald today maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a price target of $86.00. Shares of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


